|Bid||68.64 x 1400|
|Ask||68.67 x 1300|
|Day's Range||68.53 - 69.15|
|52 Week Range||53.91 - 71.65|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||20.75|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ringing today's opening bells are the U.S. Department of Agriculture with Agriculture Secretary Sonny Perdue at the NYSE and Henry Schein Financial Services with Chairman and CEO Stanley Bergman, EVP and CFO Steven Paladino, and Henry Schein Financial Services Vice President and General Manager Keith Drayer at the Nasdaq.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The latest earnings update Henry Schein, Inc. (NASDAQ:HSIC) released in December 2018 revealed...
Stocks that moved substantially or traded heavily on Tuesday: American International Group Inc., up $3.19 to $50.30 The insurer reported solid underwriting gains in the first quarter and profit beat Wall ...
Henry Schein Inc NASDAQ/NGS:HSICView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for HSIC with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HSIC totaled $6.23 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Melville, New York-based company said it had profit of 73 cents per share. Earnings, adjusted for one-time gains and costs, were 80 cents per share. The results surpassed Wall Street expectations. ...
Investing.com - Henry Schein (NASDAQ:HSIC) reported first quarter earnings that Beat analysts' expectations on Tuesday and revenue that fell short of forecasts.
is expected to report quarterly earnings of 75 cents a share on sales of $2.4 billion before the market opens on Tuesday, based on a FactSet survey of 15 analysts. Quarterly estimates have risen less than 1 cent a share in the past month. Henry Schein is currently trading at a price-to-forward-earnings ratio of 17.8 based on the 12-month estimates of 18 analysts surveyed by FactSet.
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
U.S. equities are coming under some pressure on Friday, as investors cool their heels after a run to new record highs. A surprisingly strong Q1 GDP report raised a lot of eyebrows and is calling into question hopes of Federal Reserve interest rate cuts. In fact, with energy prices rising powerfully in recent weeks, and with the economy catting a tailwind, further rate hikes cannot be dismissed.This whipsawing of sentiment is resulting in some profit-taking. And some sector rotation as well.Energy stocks, which have been hot, are cooling a bit after President Trump said he called OPEC and they are going to ramp production in response to its efforts to cut oil exports out of Venezuela and Iran. In their place, health care stocks are perking up.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 A-Rated Stocks That Are Under $10 Here are four health care stocks in the group that are worth a look now: Johnson & Johnson (JNJ) Click to EnlargeShares of Johnson & Johnson (NYSE:JNJ) look ready to push up and out of their three-month consolidation range with a challenge of triple-top resistance near the $140-a-share level. Watch for a move to the December high, which would be worth a gain of nearly 6% from here. The company announced earlier this week that it would increase its quarterly dividend by more than 5%.The company will next report results on July 16 before the bell. Analysts are looking for earnings of $2.42 per share on revenues of $20.3 billion. When the company last reported results on April 16, earnings of $2.1 beat estimates by 6 cents on a 0.1% rise in revenues. Align Technology (ALGN) Click to EnlargeShares of Align Technology (NASDAQ:ALGN), a medical device company behind products like Invisalign, are breaking out of a month-long flirtation with its 200-day moving average returning to levels not seen since late October. Watch for a return to the highs seen in September, which would be worth a gain of nearly 30% from here. * 5 Cheap Energy Stocks to Buy Under $10 The company will next report results on July 24 after the close. Analysts are looking for earnings of $1.5 per share on revenues of $596.3 million. When the company last reported on April 24, earnings of 89 cents per share beat estimates by 6 cents on a 25.7% rise in revenues. Quest Diagnostics (DGX) Click to EnlargeShares of Quest Diagnostics (NYSE:DGX) are pushing up and over their 200-day moving average, challenging the highs set back in November. This has set up a roll-up to the upper end of a sideways range that goes back to early 2017. Shares were recently upgraded by Jefferies analysts, who are looking for a price target of $107.The company will next report results on July 23 before the bell. Analysts are looking for earnings of $1.7 per share on revenues of $1.95 billion. When the company last reported on April 23, earnings of $1.40 beat estimates by 2 cents on a 0.4% rise in revenues. Henry Schein (HSIC) Click to EnlargeShares of Henry Schein (NASDAQ:HSIC), a provider of health care products and services to dental offices, is enjoying a share price breakout to levels not seen since early December. Powered with momentum from a move above both its 50-day and 200-day moving averages, watch for a challenge of recent highs near $70, which would be worth a gain of more than 10% from here. * 10 Automation Stocks to Buy for the 21st Century The company will next report on May 7 before the bell. Analysts are looking for earnings of 76 cents per share on revenues of $3.3 billion. When the company last reported on Feb. 20, earnings of $1.12 beat estimates by a penny on a 1.7% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 5 Hot Dividend Stocks to Buy as the Weather Heats Up * 7 Dividend Stocks That Could Double Over the Next Five Years * 10 Stocks to Sell Before They Give Back 2019 Gains * 7 Cloud Stocks to Buy Now Compare Brokers The post 4 Health Care Stocks That Are Starting to Heat Up appeared first on InvestorPlace.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll show how you can use Henry Schein, Inc.'s (NASDAQ:HSIC) P/E ratio to inform your assessment of the investment opportunity. H...
A few years ago I was sitting in the dentist chair for my six-month examination and teeth cleaning. As I stared at the ceiling, I couldn't help notice the name Belmont on the arm of the bright light burning a hole in my retina. I couldn't help myself, asking the dentist if she'd ever invested in a dental-related company? She said she hadn't. "Not even Henry Schein (NASDAQ:HSIC)?", I asked. Nope. That was the end of the investment discussion. Recently, I saw an article that said dental startups such as Candid and Smile Direct Club, which provides systems for mild-to-moderate teeth straightening -- saving you a bundle in the process -- have investors lining up to invest in the private companies. InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, that brought me back to that day in the dentist's chair, when I wondered about stocks to buy that will make you smile. * 10 Stocks That Are Screaming Buys Right Now Here are seven names I've identified that will put money in your pockets. Henry Schein (HSIC)Source: Shutterstock If you're a dentist, you've likely got Henry Schein on speed dial. It distributes more than 120,000 branded products and another 180,000 private label products to dentists and medical practitioners. It is the No. 1 global dental distributor and the No. 2 physician and alternate care distributor in the U.S. In fact, 90% of U.S. dental practices are active Schein customers. So, the next time you go to the dentist, be sure to ask how much stuff they buy from the company. It's probably a lot. Things seem to be going smoothly for the Melville, New York, company, yet HSIC is currently trading within 13% of its 52-week low and up less than 5% year-to-date through April 10, one-third the performance of the S&P 500.On three occasions over the past five years, it traded below $55. Within five dollars of doing so a fourth time, HSIC is entering value territory. Fear not. In 2018, Henry Schein's revenues grew by 5.9% year-over-year to $13.2 billion, while its non-GAAP earnings rose 11.4% to $635.3 million, its highest level of sales and profits in its history. Now, exclusively a company dealing with humans after spinning off its animal health business, Henry Schein is ready to take dental to the next level. 3D Systems (DDD)Source: Image via 3D Systems3D Systems (NYSE:DDD) is a 3D printer. Over the past five years as the demand for 3D printing has slowed, so too has the company's revenue and earnings growth. As a result, DDD shares have lost 80% of their value. In 2019, DDD is up more than 7% year-to-date through April 10. However, it lost a great deal of its momentum in March, giving back 23% of its gains on the year. The company's dental segment continues to take a bite out of the competition. It produces dentures, crowns and surgical guides. "There are billions of opportunities here, since virtually anybody could benefit from 3-D printed dental solutions," said CEO Vyomesh Joshi recently. On a non-GAAP basis, 3D Systems went from a $1.7 million loss in 2017 to a $16.5 million gain in 2018 on the strength of a 6% increase in revenue to $688 million. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Trading at 1.8 times revenue, less than half its five-year average price-to-sales ratio, DDD provides investors with an excellent value proposition. Align Technology (ALGN)Source: Shutterstock As dentists go, mine wasn't too pushy about trying the latest and greatest dental product or service, but she sure liked to talk up Invisalign, the $8,000 clear aligner that straightens your teeth. Made by Align Technology (NASDAQ:ALGN), I never took the bait. Now, having moved from Toronto to Halifax over a year ago, and still without a new dentist, I suspect I'll soon be getting the Invisalign sales pitch a second time. Perhaps, startups like Candid are taking a bite out of Align's market share. Given the $4,000 price over 24 months for its teeth alignment product, a good $3,000-$4,000 cheaper than the competition, it's easy to see why. However, I don't think investors should give up on ALGN just yet. As I look at the company's results for 2018, I see a lot of positives.On the top line, revenues grew 34% to $2 billion, a company record, on a 32% increase in Invisalign volume. On the bottom line, net profits were $400.2 million in 2018, 73% higher than a year ago. Forget for a moment that Invisalign didn't exist. Its iTero scanners experienced 68% growth in 2018; iTero's revenues now account for 14% of Align's overall revenue, up 290 basis points from 2017. Trading well off its all-time high of $398.88, investors buying in today, should have significant upside in the months ahead. Dentsply Sirona (XRAY)Source: Shutterstock I first became familiar with Dentsply Sirona (NASDAQ:XRAY) way back in March 2013, more than two years before Dentsply would pay $5.5 billion for Sirona Dental Systems, a company I liked because of its diversified revenue streams. "Sirona's revenue diversification is what makes it such a good company. It generates business from four operating segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments," I wrote March 20, 2013. "Its CAD/CAM and Imaging Systems accounted for 70% of its overall revenue in the first quarter ended December 2012."If you took my advice and bought 100 shares of Sirona at the Q2 2013 high of $73.98, today you'd have $9,158, a 24% return. But over three years, it's seen a mediocre 5% return. So, do I still think XRAY is worth holding for the long haul?I do. Here's why.Like most acquisitions, the tie-up didn't go nearly as smoothly as hoped. As a result, the company was forced to implement a turnaround plan that will simplify its business. Where have I heard that before?Anyway, when you bring together two reasonably large businesses, you often lose focus on parts of it and those units suffer. So, it's exiting these businesses and cutting staffing by as much as 8%. By fiscal 2020, analysts expect it to earn $2.64 a share, its best earnings performance since 2016. * The 7 Best Long-Term Stocks for 2019 And Beyond It has had a good run in 2019, up 36% year-to-date. I'd be patient and try to buy on weakness in the mid-$40s. Patterson Companies (PDCO)Source: Shutterstock A little over two years ago, Globe and Mail business reporter Scott Barlow highlighted 12 healthcare stocks that had stable cash flow. He argued that businesses such as Patterson Companies (NASDAQ:PDCO), a distributor of dental and animal health products, would make you rich over the long haul because of this critical attribute. Since the article, PDCO stock has lost approximately half its value. Ouch.However, in the nine months ended Jan. 27, 2019, Patterson's operating cash flow increased 91% to $76.3 million. After subtracting $33.9 million in capital expenditures, it generated free cash flow of $42.4 million or 77% of its net income. On the top line, revenues in the first three quarters of fiscal 2019 barely budged, up 1.8% to $4.14 billion. On the bottom line GAAP basis, its net income fell 69% to $55.2 million. On an adjusted basis, earnings fell 25% to $95.9 million. While this article is about dental businesses, Patterson's animal health business (58% of revenue) continues to provide PDCO with diversified revenue streams that will protect it when the economy turns south because a lot of pet owners won't scrimp on their companion animal's wellbeing. Yielding 4.8% at the moment, it has plenty of free cash flow to keep paying its juicy dividend. If you're an income investor, PDCO is an excellent stock to own before the company's restructuring takes hold. Get paid to wait. Procter & Gamble (PG)Source: Mike Mozart via Flickr (Modified)My old dentist's dental technician recommended that I buy an Oral-B electric toothbrush because it does a better job of brushing your teeth without overdoing it, thus hurting your gums. She was right. Originally invented in 1950 by California periodontist Dr. Robert Hutson, he sold the company to Cooper Laboratories, who in turn sold it to Gillette in 1984 for $188.5 million. The rest, as they say, is history. On April 9, Oral-B's owner, Procter & Gamble (NYSE:PG), raised its quarterly dividend by 4% to 74.59 cents a share, an annualized rate of $2.98, yielding 2.8% despite a 37% gain over the past 52 weeks. This is P&G's 63rd consecutive year increasing its dividend. Oral-B and the rest of its oral care brands generated 9% of P&Gs revenue in the second quarter. Part of the healthcare segment, sales and earnings were both up slightly in the first quarter, delivering solid if not spectacular results. * The 10 Fastest-Growing Stocks to Invest In Right Now Consider Oral-B the company's slow-growth business. Overall, however, Procter & Gamble is doing just fine. Church & Dwight (CHD) Source: slgckgc via Flickr (Modified)Church & Dwight (NYSE:CHD) is a smaller version of P&G. But make no mistake, it competes with the best of them. As far as dental care goes, it has Arm & Hammer, AIM, Close-Up and Pepsodent toothpaste. Other brands include Orajel and Waterpik. The company has become adept at making smaller acquisitions and then growing those businesses over time. Most recently, it announced it had acquired two hair removal brands, Flawless and Finishing Touch, for $475 million and a further $425 million in potential earnouts. The two brands add $180 million in annual revenue and $55 million in EBITDA.The owners of Flawless would have been wise to ask for stock instead of cash because over the past decade, CHD stock has delivered an annualized total return of 19.4%, almost double P&G.As stocks go, CHD is a perfect 10. I urge you to check it out. At the time of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post 7 Dental Stocks to Buy That Will Make You Smile appeared first on InvestorPlace.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Analyzing Henry Schein, Inc.'s (NASDAQ:HSIC) track record of past performance is a valuable exercise for investors. It enable...
We can judge whether Henry Schein, Inc. (NASDAQ:HSIC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Many investors define successful investing as beating the market averageRead More...
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.